Fig. 1From: Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry studyProbability to gain the ability to walk independently. Probability to gain the ability to walk independently under treatment with nusinersen in younger sitters (red) and older sitters (blue). Numbers at risk are listed for dedicated time-points. Colored areas indicate 99% confidence intervalsBack to article page